Phase 3 clinical trial results demonstrating that semaglutide 2.4 mg (Wegovy, Novo Nordisk) reduces the incidence of major cardiovascular events (MACE) may enable the drug to be administered by doctors to patients with insurance coverage, as a therapy to prevent cardiovascular disease (CVD).
“This is the first time we have evidence that obesity treatment with an anti-obesity medication has the impact of reducing cardiovascular events,” commented Jamy Ard, MD, the